Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.
Yokohama, Japan - March 14th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and VectorBuilder Inc. have entered into a business alliance. Details in Japanese for local news in Japan. Minaris Regenerative Medicine株式会社（本社：神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris）は、VectorBuilder Inc.（本社：Chicago, IL 60609, USA、最高科学責任者 Bruce Lahn, Ph.D.、以下 VectorBuilder）と業務提携を結んだことをお知らせします。 ...
Munich, Germany - November 28th, 2023 - Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry fully owned by Resonac Group, announces the appointment of Hiroto Bando, PhD as CEO of the European operations of Minaris Regenerative Medicine (Minaris) as of November 28, 2023. Hiroto Bando assumes this new role ...
JERSEY CITY, N.J. - September 6th, 2023 - Apprentice.io, leading technology provider for life sciences manufactures, announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, has selected Apprentice’s Tempo Manufacturing Execution System (MES) to digitize its commercial manufacturing in North America and ...
Pleasanton, CA - May 24, 2023 - Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. Minaris Regenerative Medicine will use Veeva’s unified quality applications to ...
LONDON, UK and MUNICH, GERMANY - February 16, 2023 - LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a leading global contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a development and ...
MUNICH, GERMANY - December 7, 2022 - Minaris Regenerative Medicine is pleased to announce that, effective December 1, 2022, Helmut Lerch, PhD, who joined the company in July of this year as Head, Quality Management for Minaris Regenerative Medicine GmbH (the company’s Germany region) will assume the role of Global Quality Head, succeeding Jacqueline Veivia-Panter. Helmut is an accomplished ...
Munich, Germany, and Stockholm, Sweden - Oct 28, 2022. Mendus AB (“Mendus publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence and Minaris Regenerative Medicine GmbH („Minaris“), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have extended their manufacturing partnership for technology ...
Tokyo, Japan - October 13, 2022. Showa Denko Materials Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and CEO: Hidehito Takahashi; hereinafter “Showa Denko Materials”) and Kidswell Bio Corporation (Head office: Chuo-ku, Tokyo; President and CEO: Masaharu Tani; hereinafter “Kidswell Bio”) entered into an agreement to enable process development as well as clinical manufacturing...
Allendale, NJ, USA and Yokohama, Japan - October 12, 2022 - Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment...
London, UK and Munich, Germany - June 27, 2022 - Ixaka Ltd Minaris Regenerative Medicine GmbH today announced that they have signed an agreement to enable technology transfer as well as clinical and commercial manufacture of REX-001.
Allendale, N.J., USA and Yokohama, Japan - Dec. 20, 2021 - Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership. Hiroto Bando, PhD, who joined Minaris Regenerative Medicine as Deputy General Manager.
ALLENDALE, NJ - September 9, 2021 - Minaris Regenerative Medicine (United States) welcomes Emmanuelle Bommier in the role of Senior Director, Business Development, effective August 30, 2021. In her role as head of business development for North America, reporting to CEO, Dr. Kazuchika Furuishi, Emmanuelle will be accountable for creating new business opportunities and client management for ...
MUNICH, Germany – July 21, 2021 - Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for SkysonaTM (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for ...
ALLENDALE, NJ., USA, MUNICH, GERMANY, and YOKOHAMA, JAPAN – June 28, 2021— Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership. Minaris Regenerative Medicine, having facilities in the U.S., Germany, and Japan, will shift to a model of regional operational leadership on October 1, 2021. Under the new model, its three regional Chief ...
GENEVA, Switzerland and MUNICH, Germany – Feb 22, 2021 —MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy ...
MUNICH, Germany – January 25, 2021- Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry fully owned by Showa Denko Materials Co., Ltd., announces the appointment of Dusan Kosijer as CEO of the European operations of Minaris as of January 1, 2021. Dusan Kosijer has served as Chief Financial Officer of ...
WORCESTER, Mass. and MUNICH, Germany– Nov 23, 2020 — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and ...
Munich, Germany and Yokohama, Japan – Nov. 2, 2020 — Minaris Regenerative Medicine (“Minaris”), a leading global contract development and manufacturing organization for cell and gene therapies, wholly owned by Showa Denko Materials Co., Ltd., announced today a total investment of 64.5 million USD to significantly expand its facilities in Europe and Asia. European Facility Expansion: A new state ...
Allendale, NJ., USA, Munich, Germany, and Yokohama, Japan-Sept. 23, 2020-The regenerative medicine business of Hitachi Chemical Co., Ltd. (“Hitachi Chemical”) announces that, effective today, it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry. “By working and using the single ...
ALLENDALE, NJ. and MUNICH, GERMANY.-- May 11, 2020-- Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), both subsidiaries of Hitachi Chemical Co., Ltd. (Hitachi Chemical), today announced that they have expanded their relationship with bluebird bio (NASDAQ: BLUE) with long-term development and manufacturing services agreements for clinical and ...
The entire team at HCATS continues its commitment to stay ahead of and respond to the COVID-19 situation. At this time, our facilities continue operations and all our amazing employees are working exceptionally hard through these challenging circumstances to provide our clients with the high-quality support they are accustomed to and deserve. Although both Bergen County, New Jersey and Santa ...
At HCATS, we are dedicated to providing our clients with high value development and manufacturing services while fostering a safe environment that does not put our patients, clients, or employees at risk. Due to this and the growing concern of COVID-19, we are taking necessary precautions and implementing new policies and procedures so we can continue to work toward making transformative ...
Company Expects to Add Up to 500 Employees in New Jersey Hitachi Chemical Advanced Therapeutics Solutions, LLC (“HCATS”), a subsidiary of Hitachi Chemical Co., Ltd. representing Hitachi Chemical’s Regenerative Medicine Business Sector (“RMBS”) in North America, today announced the opening of its new cell and gene therapy manufacturing facility in Allendale, New Jersey. The new facility is the ...
For 20 years, Hitachi Chemical Advanced Therapeutics Solutions (HCATS) has helped clients to improve their cell-based therapy development and manufacturing processes. The client-focused mindset of our PCT global service platform allows our team to easily facilitate technology transfers, accelerate time to market, and reduce the costs and risks of clinical development programs. And now the future ...
Munich, Germany, January 13, 2020 - apceth Biopharma GmbH, a subsidiary of Hitachi Chemical Co., Ltd. and a leading company for the manufacturing of cell and gene therapeutics, starts the commercial manufacturing of ZyntegloTM ▼, a product of bluebird bio, Inc. Today bluebird bio announced the market entry of its gene therapy Zynteglo in Germany, the first country globally where Zynteglo is ...
Munich, Germany, June 4, 2019 - apceth Biopharma GmbH, a leading company for the manufacturing of cell and gene therapeutics, will operate as the commercial manufacturer in Europe for ZyntegloTM, a product of bluebird bio. Yesterday the European Commission (EC) has granted conditional marketing authorisation for ZyntegloTM, a gene therapy for patients 12 years and older with transfusion-dependent ...
April 9, 2019 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of cell therapy products, and Saint-Gobain, a global leader in single-use solutions for the Biopharmaceutical industry, today announced a joint development agreement to co-develop and commercialize novel technology ...
April 3, 2019 – We are pleased to announce that Hitachi Chemical Co. Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Hisashi Maruyama; hereinafter “Hitachi Chemical”) has completed its acquisition of apceth Biopharma GmbH (Head Office: Munich, Germany; CEO: Dr. Christine Guenther; hereinafter “apceth Biopharma”), a contract manufacturer of cell and gene therapy products, adding its ...
Allendale, NJ, United States, January 31, 2019 - Hitachi Chemical Advanced Therapeutics Solutions, LLC announces an agreement by which apceth Biopharma GmbH (“apceth Biopharma”), a contract manufacturer of cell and gene therapy products, will join Hitachi Chemical’s PCT global services platform. apceth Biopharma manufactures cell and gene therapy products for American and European clients through ...
Allendale, NJ, United States, January 29, 2019 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) announced it has successfully completed the technology transfer and implementation of the manufacturing process and commenced manufacturing services for dosing of patients in MaxCyte, Inc.’s Phase I dose-escalation clinical trial of MCY-M11 in the United States. MaxCyte MCY-M11, its ...
Munich, Germany, November 16, 2018 - apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, has started supplying clinical batches of DCprime’s cell-based cancer vaccine DCP-001 to a phase II clinical study for the treatment of Acute Myeloid Leukemia (AML). AML is a haematological cancer characterized by high risk of relapse, even after ...
Munich, Germany, Oct 5th, 2018 - apceth Biopharma GmbH, a leading company for the development and manufacturing of cell and gene therapeutics, congratulates its partner bluebird bio on the acceptance and validation of its market authorization application by the European Medicines Agency (EMA). bluebird bio has applied for market authorization of its investigational LentiGlobin™ gene therapy for ...
Allendale, NJ, United States, October 1, 2018 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) announced today that they have signed a three-year clinical manufacturing agreement with GSK, a science-led global healthcare company. Under the agreement, HCATS will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials. NY-ESO is ...
NEW BRUNSWICK, NJ – Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a U.S. subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of regenerative medicine products, and Rutgers University–New Brunswick’s School of Engineering today announced a collaboration to launch a graduate-level course, “Integrative Molecular and Cellular ...
After three years of operations leadership for Hitachi Chemical Advanced Therapeutics Solutions (HCATS), William (Bill) Monteith will be leaving HCATS with transition expected to complete by November 2018. Brian Hanifin will fill the role of Interim Head of Technical Operations for HCATS. Brian has 25+ years of extensive pharmaceutical experience leading internal company plants. He has been an ...
March 19, 2018 - Hitachi Chemical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Hisashi Maruyama; hereinafter “Hitachi Chemical”) announces the signing of an agreement with Daiichi Sankyo Co., Ltd. (Head Office: Chuo-ku, Tokyo; hereinafter “Daiichi Sankyo”) for clinical manufacturing*1 of Regenerative Medicine developed by Daiichi Sankyo for the Japanese market. Hitachi Chemical ...
Tokyo, Japan, March 13, 2018—SanBio Group and Hitachi Chemical Co., Ltd. (Hitachi Chemical) jointly announced today that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LCC (HCATS; formerly PCT Cell Therapy Services, LLC), Hitachi Chemical’s U.S. subsidiary that engages in contract manufacturing and development of regenerative medicine products1, they will manufacture ...
We at Hitachi Chemical Advanced Therapeutics Solutions, LLC are excited to announce that construction on additional PCT GMP manufacturing infrastructure and cleanroom capacity has begun at our newly-leased 49,700 square foot facility in Allendale, New Jersey (“75 Commerce”) in addition to upgrades to our existing facility at 4 Pearl Court, Allendale (“4 Pearl Court”). The upgrades will allow us ...
Leiden, The Netherlands, and Munich, Germany, October 19, 2017 - DCPrime BV, a clinical stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement. The collaboration involves clinical batch ...
Yokohama, Japan, October 19, 2017: Hitachi Chemical Co., Ltd. (HCC), a global service provider for the cell therapy industry through its PCT development and manufacturing service platform, today announced the completion of construction and opening of its Yokohama, Japan facility on October 11. This facility, as well as the existing two U.S. PCT facilities, will share the same global PCT service ...
Allendale, NJ, USA, October 10, 2017 Today, Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a global service provider for the cell therapy industry through its PCT development and manufacturing platform, announced the planned expansion of its PCT service platform through the addition of GMP manufacturing infrastructure and cleanroom capacity in Allendale, NJ. The expansion includes ...
Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with rare diseases of high unmet medical need announces today that it has entered a new clinical manufacturing services agreement with PCT Cell Therapy Services, LLC (“PCT”), a Hitachi Group Company. PCT is a leading provider of contract services ...
We are pleased today to announce a significant upcoming transformation for our company and enhancements to our capabilities to serve our valued clients. Hitachi Chemical Co. America, Ltd. (Hitachi Chemical), our collaborator and currently minority owner of PCT, has entered into an agreement with Caladrius Biosciences, majority owner of PCT, to purchase Caladrius’ remaining share of PCT, with an ...
CD34+ CD45- Cells Isolated from Human Blood Have Molecular and Functional Characteristics of Vascular Endothelial Progenitors Rare CD45- cells have been described in human blood, bone marrow and umbilical cord blood that lack blood cell lineage markers (Lin-) but express antigens (CD34 and/or CD133) associated with hematopoietic (blood cell) progenitors. This is in contrast to typical ...
PCT announces that Robert A. Preti, Ph.D., the Company’s Chief Technology Officer, President of PCT, has been named Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapies and broader regenerative medicine sector. Dr. Preti has served as Vice Chairman of ARM since January 2015 and succeeds Edward Lanphier as ...
PCT has expanded its relationship with Kiadis Pharma (Euronext Amsterdam and Brussels: KDS) (“Kiadis”), by entering into an agreement for the manufacturing of cell therapy product for United States and Canada clinical trial sites for a Phase 3 trial of Kiadis’ lead product, ATIR101™, for the treatment of blood cancers. To date, PCT has provided engineering and process development services for ...
PCT leaders will offer their perspective on cell therapy manufacturing of the future at this month’s Phacilitate Cell and Gene Therapy World conference. Through presentations and an interactive panel discussion, PCT will outline the framework that enables successful product commercialization over the long-term. Offering an approach to cell therapy manufacturing grounded in Development by Design ...
ALLENDALE, N.J., Sept. 8, 2015 -- PCT, LLC, A Caladrius Company (PCT), the manufacturing sciences and technical operations subsidiary of cell therapy leader Caladrius Biosciences (NASDAQ:CLBS) and leading external manufacturing partner to the cell therapy industry, announced today that it will expand its current manufacturing capacity at PCT's Allendale, New Jersey facility to support IRX ...
New York (June 15, 2015) – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius”), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today a new Agreement between its wholly-owned subsidiary, PCT, LLC, a Caladrius Company (“PCT”), and ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC), a clinical-stage company that is developing ...
New York, N.Y. April 30, 2014 -- NeoStem, Inc. (NASDAQ:NBS) and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), announced the execution of a Services Agreement with IRX Therapeutics, Inc. (“IRX”) under which PCT will provide services to support IRX’s development of IRX-2, a primary cell-derived biologic with multiple active cytokine components. IRX-2 is a cancer therapeutic designed to ...
March 10, 2014 — NeoStem, Inc. (NASDAQ:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), an internationally recognized contract development and manufacturing organization, announced today that PCT has expanded both its Allendale, NJ and Mountain View, CA current Good Manufacturing Practice (“cGMP”) ...
New York, Jan. 13, 2014 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that NeoStem and PCT will present at five sessions at the Phacilitate Cell & Gene Therapy Forum 2014 ...
Services Will Utilize Additional Clean Room Capacity Recently Added to PCT's California Facility NEW YORK, Jan. 9, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), announced today the execution of a Services Agreement with Kite Pharma, Inc., under which PCT will provide cell therapy process development and manufacturing services for ...
New Process Development Improvements Intended to Ensure Phase 3 and Commercial Readiness for Client New York, NY, December 3, 2013-- NeoStem, Inc. (Nasdaq:NBS), and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), announced the expansion of PCT’s relationship with ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC), a clinical-stage company that is developing immune-based ...
PCT to Provide Cell Product Development and Manufacturing for Adaptimmune's Clinical Trials Allendale, N.J. and Oxford, United Kingdom, Jan. 16, 2013 -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services ...
Allendale, N.J. and Hackensack, N.J., Jan. 7, 2013 -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization (CDMO), and Hackensack University Medical Center ("HackensackUMC"), part of the Hackensack University Health Network and a hub of healthcare for the Northern New Jersey and New ...